Information:
Fel:
ID
13712
Beskrivning
Telaprevir, Peg-IFN-alfa-2a, and RBV in Treatment-Experienced Black/African American and Non-Black/African American Subjects With Genotype 1 Chronic Hepatitis C; ODM derived from: https://clinicaltrials.gov/show/NCT01467492
Länk
https://clinicaltrials.gov/show/NCT01467492
Nyckelord
Versioner (1)
- 2016-02-29 2016-02-29 -
Uppladdad den
29 februari 2016
DOI
För en begäran logga in.
Licens
Creative Commons BY 4.0
Modellkommentarer :
Här kan du kommentera modellen. Med hjälp av pratbubblor i Item-grupperna och Item kan du lägga in specifika kommentarer.
Itemgroup-kommentar för :
Item-kommentar för :
Du måste vara inloggad för att kunna ladda ner formulär. Var vänlig logga in eller registrera dig utan kostnad.
Eligibility Hepatitis C NCT01467492
Eligibility Hepatitis C NCT01467492
- StudyEvent: Eligibility
Similar models
Eligibility Hepatitis C NCT01467492
- StudyEvent: Eligibility
Name
Typ
Description | Question | Decode (Coded Value)
Datatyp
Alias
ethnic group
Item
participants self-identify as black/african american (group a) or did not self-identify as black/african american (group b)
boolean
C0015031 (UMLS CUI [1])
chronic hepatitis c; hepatitis c genotype
Item
participants have genotype 1 chc and laboratory evidence of hepatitis c virus (hcv) infection for at least 6 months
boolean
C0524910 (UMLS CUI [1])
C1148363 (UMLS CUI [2])
C1148363 (UMLS CUI [2])
dosage study drug
Item
participants did not achieve sustained viral response 24 weeks after last dose of study drug (svr24), after at least 1 prior course of peg-ifn-alfa-2a/rbv therapy of standard duration
boolean
C0178602 (UMLS CUI [1,1])
C0013227 (UMLS CUI [1,2])
C0008972 (UMLS CUI [1,3])
C0013227 (UMLS CUI [1,2])
C0008972 (UMLS CUI [1,3])
concomitant therapy telaprevir protease inhibitor
Item
participants have received previous treatment with telaprevir or any other protease inhibitor(s) for chc
boolean
C1707479 (UMLS CUI [1,1])
C1876229 (UMLS CUI [1,2])
C0033607 (UMLS CUI [1,3])
C1876229 (UMLS CUI [1,2])
C0033607 (UMLS CUI [1,3])
hepatic decompensation
Item
participants who have evidence of hepatic decompensation
boolean
C0085605 (UMLS CUI [1])
hepatocellular carcinoma
Item
participants have diagnosed or suspected hepatocellular carcinoma
boolean
C2239176 (UMLS CUI [1])
liver disease
Item
participants have any other cause of significant liver disease in addition to hcv
boolean
C0023895 (UMLS CUI [1])
Substance Use Disorder
Item
participants are currently abusing illicit drugs or alcohol, or have history of illicit substance or alcohol abuse within 2 years before the screening visit
boolean
C0038586 (UMLS CUI [1])
Study Subject Participation Status
Item
participants who participated in any investigational drug study within 90 days before dosing
boolean
C2348568 (UMLS CUI [1])